Ucb, new data in rheumatology at Eular 2021

Ucb, a global biopharmaceutical company, has presented new data for its Fc fragment-free anti-TNF, Cimzia * (certolizumab pegol), and its experimental Il-17L and IL-17F inhibitor, bimekizumab, at the European Rheumatology Congress ( Eular) 2021, just concluded. Seven abstracts were accepted for the E-Congress and all – reports a company note – highlight UCB’s commitment to guarantee innovation in rheumatology and address the unmet needs of patients. Three of the seven abstracts were presented as posters with guided narratives and live Q&A sessions. “The information presented at Eular reflects our innovative research in rheumatology and prepares us for a promising future. This important event has provided the opportunity to link our scientific innovation to the gaps and barriers that still exist in the pathways of rheumatology patients” The data from certolizumab pegol include a post-hoc analysis of the phase 3b C-Optimise study in axSpA, Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of US, Ucb said. The analysis evaluated disease activity and clinical markers of inflammation in patients who did not have flare after randomization to maintenance full-dose certolizumab pegol (200 mg every two weeks), maintenance-reduced certolizumab pegol ( 200 mg every four weeks) or placebo in weeks 48-96 of the C-Optimise study. The analysis identified higher disease activity and an increase in serological and inflammatory biomarkers in patients randomized to placebo who did not relapse during weeks 48-96 of the C-Optimise study, compared to those who remained on treatment with certolizumab pegol. The results confirm that patients with axSpA who achieve sustained remission over time benefit from continuing certolizumab pegol treatment, either with the full or reduced maintenance dose – compared to discontinuing treatment. – include the two-year results of the open-label phase 4 study, C-View, which examined the impact of certolizumab pegol treatment on acute anterior uveitis (Aau) in patients with axSpA and a recent history of flare Aau, and a post-hoc analysis from a 52-week placebo-controlled interventional study in nr-axSpA (C-axSpAnd) to identify MRI positivity for sacroiliac joint involvement and positivity for sacroiliac joint involvement. baseline human leukocyte antigen B27 (Hla-B27) as predictors of clinical response to certolizumab pegol treatment at week 52. Ucb shared an analysis prospective that includes data from more than 1,000 pregnancies with exposure to certolizumab pegol at least in the first trimester, representing one of the largest cohorts of pregnancies with known outcomes in patients living with axSpA, CD, PsA, PSO and RA who have been exposed to an organic. No increase in adverse pregnancy outcomes or specific congenital malformations was observed in pregnancies treated with certolizumab pegol compared to the general population. The data – concludes the note – further confirmed the influence of confounding factors, such as specific chronic inflammatory diseases (Cid), concomitant drugs or comorbidities, on the outcome of pregnancy. Taken together, these data offer additional information for healthcare professionals considering certolizumab pegol treatment as clinically necessary for their patients of childbearing potential.